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Abstract
OBJECTIVE: To determine the effect of Houttuynia
cordata Aetherolea on connective tissue growth
factor and adiponectin in a rat model of diabetes
mellitus (DM).
METHODS: DM was induced in rats using strepto-
zotocin (STZ) and high glucose-lipid animal feed.
Animals were then treated with Houttuynia cordata
Aetherolea for 8 weeks. Changes in connective tis-
sue growth factor and adiponectin levels in rats
were observed.
RESULTS: Connective tissue growth factor and adi-
ponectin levels in rats with DM improved after
Houttuynia cordata Aetherolea treatment.
CONCLUSION: Houttuynia cordata Aetherolea had
a positive effect on rats with DM by reducing levels
of connective tissue growth factor and increasing
adiponectin levels.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Houttuynia cordata is a plant herb belonging to the
Saururus chinensis (Lour.) Bail. Houttuynia cordata
Thunb. family. According to Chinese medicine, Hout-
tuynia cordata has a cold nature, and is acrid and bitter
in flavor. This herbal plant has the ability to relieve su-
perficies by cooling and inducing diuresis to reduce
edema. In a clinical setting, it is used to treat lung ab-
scesses, pyemesis, dyspnea associated with cough due
to excessive phlegm, micturition disorders, and ulcers.
The fresh plant contains volatile oils (0.0049% ), and
its essential component is Houttuynin, which is also
known as decanoylacetaldehyde. The volatile oil of the
Houttuynia cordata plant was intragastrically adminis-
tered to rats with diabetes mellitus (DM) for 8 weeks.
We found that Houttuynia cordata reduced urine pro-
tein levels and renal lesions in diabetic rats. In order to
understand the mechanism involved, we designed a se-
ries of experiments to identify the effect of Houttuynia
cordata volatile oils on DM rats by monitoring adipo-
nectin and connective tissue growth factor (CTFG) lev-
els. Adiponectin is excreted by adipose tissue and plays
an important role in insulin sensitivity and the phlogis-
tic process. In addition, adiponectin has been linked to
adipositas cordis, type 2 DM and IR[1], while CTGF
has been shown to play an important role in the occur-
rence and development of kidney hypertrophy. Rosigli-
tazone functions to decrease the albumin excretion
rate, and can markedly improve insulin resistance in di-
abetic rats[2], while Losartan can reduce urine protein
levels during diabetic nephropathy[3], and can also in-
crease insulin sensitivity in diabetic and hypertensive
patients[4].
MATERIAL ANDMETHODS
Animals
Clean male Wistar rats (3 months old), weighing
180-200 g, were provided by the Shanghai Laboratory
Animal Center [Shanghai, China, Certification code:
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SYXK(沪)2004-0005]. Rats were housed in the SPF
Laboratory Animal Center of Shanghai University of
Traditional Chinese Medicine under a 12 h light/dark
cycle, and had free access to food and water. The center
was maintained at a constant temperature and humidity.
Herbal and Commercial Medicines
Houttuynia cordata was obtained from the Shanghai
Xuhui Chinese Medicine Decoction Pieces Factory
(Shanghai, China). The Houttuynia cordata volatile oil
was extracted using the wet distillation method. Losar-
tan (50 mg tablets) was purchased from Merck & Co.,
Inc. (Hangzhou, China), Rosiglitazone (4 mg tablets)
was purchased from GlaxoSmithKline (Tianjin, Chi-
na), and streptozotocin (STZ) was from Sigma-Aldrich
Co. (St. Louis, MO, USA).
Animal Groupings
Sixty male Wistar rats, after 1 week of adaptive feed-
ing, were divided into 3 groups. The mockup group
(n=51) was fed a high-carbohydrate and high-fat diet[5]
(20% (w/v) sucrose, 10% (w/v) axungia porci, 2.5%
(w/v) cholesterol, and 67.5% (w/v) common diet) ev-
ery day, and had free access to drinking water. The con-
trol group (n=9) was fed the common diet. After 30
days, the mockup group was food restricted for 12 h.
STZ was dissolved in 0.1 mol/L citric acid buffer (pH
4.0) to a concentration of 0.1% (w/v). The STZ solu-
tion was then intraperitoneally injected into rats at a
dose of 30 mg/kg. After 72 h, fasting blood sugar and
urine glucose were detected using the one touch II glu-
cometer and glucose reagent strips (Lifescan Inc., Mil-
pitas, CA, USA), and the Hitachi type 7170 automatic
biochemistry analyzer (Hitachi Ltd., Tokyo, Japan), re-
spectively. Successful induction of DM in 50 rats was
achieved when blood sugar levels were > 16.7 mmol/L
and urine protein output increased by 50% when com-
pared with data before mockup. Equivalent amounts of
citric acid buffer were intraperitoneally injected into
control animals. Rats in the mockup group were ran-
domly divided into 5 sub-groups: 1) Houttuynia corda-
ta water solution group (5400 mg/kg/day Houttuynia
cordata in 2 mL water), 2) Houttuynia cordata volatile
oil group (5400 mg/kg/day 2 mL Houttuynia cordata
volatile oil suspension), 3) Losartan group (30 mg/kg/
day Losartan, dissolved in 2 mL water), 4) Rosigli-
tazone group (30 mg/kg/day Rosiglitazone dissolved in
2 mL water), and 5) model group (given equivalent
amount of water).
Detection Index
Changes in drinking consumption, food consumption,
and body weight of all animals were monitored at the
end of the fourth and eighth week. At the end of the
eighth week, rats were anesthetized by intraperitoneal
injection of pentobarbital sodium (40 mg/kg). Blood
samples were collected from rats to measure fasting
plasma glucose (FPG), fasting serum insulin (FINS),
blood serum adiponectin, and CTGF levels and the in-
sulin sensitivity index. The kidneys of rats were resect-
ed to measure tissue adiponectin levels using the en-
zyme linked immunosorbent assay (ELISA). The insu-
lin sensitivity index (ISI) was calculated as follows.
ISI=-Ln1/FINS*FPG[6]
Statistical Analysis
All data were analyzed using SPSS 10.0 (IBM, Ar-
monk, NY, USA), and are expressed as the mean ± s.e.
m. Statistical analyses were performed using one-way
analysis of variance. When heterogeneity of variance ap-
peared, the Dunnet T3 multiple comparison test was
used. A value of P<0.05 was considered statistically sig-
nificant.
RESULTS
Rats in the control group had good mental status and
remained active (they were alert and their pelt was
glossy). After 1 month on a high-carbohydrate and
high-fat diet, the body weight and food intake of rats
in the mockup group increased. After injection with
STZ for 4 weeks, food intake remained high, but body
weight only increased slightly when compared with the
control group. The weight of rats in the model group
decreased after injection with STZ, but rats suffered
from polydipsia and polyuria, were mentally dispirited,
were unresponsive, their pelt was no longer glossy, and
they became slow. Animals in all the therapeutic
sub-groups of the mockup group showed better mental
condition and agility, but were less responsive when
compared to the control group.
FPG levels in the model group, Houttuynia cordata wa-
ter solution group and the Losartan group were signifi-
cantly higher than the control group (P<0.05; Table
1). There were no significant differences between any
of the sub-groups of the mockup group. All therapeu-
tic sub-groups had significantly lower blood glucose
levels when compared with the model group (P<0.05;
Table 1). In the model, Houttuynia cordata water solu-
tion and Losartan groups, FINS levels were significant-
ly increased when compared to the control group (P<
0.05; Table 1). At the same time, high blood glucose
levels existed in these diabetic rats, indicating that
there was insulin resistance.
FINS levels in the Houttuynia cordata volatile oil
group and Rosiglitazone group were significantly lower
(P<0.05; Table 1) than the model group. Moreover,
FINS levels in the Houttuynia cordata water solution
and Losartan groups were significantly higher when
compared with the Houttuynia cordata volatile oil and
Rosiglitazone groups (P<0.05; Table 1).
The ISI for the Houttuynia cordata volatile oil group
and Rosiglitazone (insulin sensitizer) group was signifi-
cantly higher when compared with the model and
Losartan groups (P<0.05; Table 1).
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Table 1 Influence of Houttuynia cordata Aetherolea on FPG, FINS, and the ISI in diabetic rats ( xˉ ±s)
Group
Control
Model
Houttuynia cordata water solution
Houttuynia cordata volatile oil
Losartan
Rosiglitazone
n
9
10
10
10
10
10
dosage
-
-
5400 mg·kg-1·d-1
5400 mg·kg-1·d-1
30 mg·kg-1·d-1
3 mg·kg-1·d-1
FPG/mmol·L-1
6.01±1.13
11.59±4.21#
9.02±2.24#*
7.75±1.96*
8.21±2.20#*
7.53±1.75*
FINS/μ·mL-1
23.01±4.75
37.52±8.85#
34.16±12.89#△+
27.52±5.47*
37.21±13.17#△+
25.13±4.34*
ISI
-4.34±0.49
-6.99±0.50#△+
-5.64±0.53#
-5.31±0.38#
-5.99±0.32#△+
-5.12±0.18#
Note: #P<0.05 vs. control group; *P<0.05 vs. model group; △P<0.05 vs. Houttuynia cordata volatile oil group; +P<0.05 vs. Rosiglitazone
group.
CTGF levels in the model group and the Western med-
icine groups were significantly higher than the control
group (P<0.05; Table 2). However, levels in both the
Houttuynia cordata water solution group and Hout-
tuynia cordata volatile oil group were significantly low-
er than the Western medicine and model groups (P<
0.05; Table 2).
Serum and tissue adiponectin levels in the model and
all therapeutic groups were lower than the control
group. However, adiponectin levels in the Houttuynia
cordata water solution group and Houttuynia cordata
volatile oil group were significantly higher than the
model group (P<0.05; Table 2). Adiponectin levels in
the Rosiglitazone groups was significantly lower than
in the Houttuynia cordata volatile oil group (P<0.05;
Table 2).
Table 2 Serum/tissue levels of adiponectin and CTGF in diabetic rats ( xˉ ±s)
Group
Control
Model
Houttuynia cordata water solution
Houttuynia cordata volatile oil
Losartan
Rosiglitazone
n
9
10
10
10
10
10
Tissue adiponectin (μg/mL)
14.32±3.35
10.13±2.86#
13.18±4.23*
13.68±3.04*
11.81±2.34#△
11.45±1.49#△
Serum adiponectin (μg/mL)
5.07±1.38
2.83±0.85#
4.29±1.57*
4.73±0.74*
4.27±1.45*
3.87±0.76△
CTGF (pg/mg)
6.10±0.69
9.14±0.31#
6.39±0.52*
6.70±0.64*
8.03±1.12#*△
7.70±2.06#*△
Note: #P<0.05 vs. control group. *P<0.05 vs model group. △P<0.05 vs. Houttuynia cordata volatile oil group.
DISCUSSION
Houttuynia cordata volatile oil was extracted by distilla-
tion from the Houttuynia cordata plant. The essential
component of this herb is Houttuynin, which has bac-
teriocidal, antiblastic, antivirotic, anti-inflammatory,
urinative, and antilipemic effects, and has an an-
ti-blood platelet congregating function. Some studies
have shown that Houttuynia cordata can inhibit hyper-
trophy of the kidney glomerulus, decrease urea β2-mi-
croglbulin levels, the urea albumin excretion rate and
creatinine clearance rate within 24 h[7]. Rosiglitazone
functions to decrease the albumin excretion rate[8],
and can markedly improve insulin resistance in diabet-
ic rats[9-10], while Losartan can reduce urine protein lev-
els during diabetic nephropathy[3], and can also increase
insulin sensitivity in diabetic and hypertensive patients
[4]. In this study, we identified how Houttuynia cordata
may improve diabetic nephropathy via the following
mechanisms:
Improvement of insulin resistant (IR)
The development of DM is very complex. Currently,
DM is believed to be related to IR and/or the lack of
beta cell insulin secretion. The insulin required to stim-
ulate skeletal muscle intake of glucose is more than the
quantity of insulin needed to inhibit the production
and output of hepatic glycogen[11]. Therefore, postpran-
dial blood glucose increases, and consequently fasting
blood glucose increases. When IR becomes serious, be-
ta cell failure, due to long term overcompensation, and
disruption to glycometabolic control is gradually exac-
erbated. When blood glucose levels increase and contin-
ue to persist, DM can occur[12].
IR can be regarded as the efficiency of insulin to medi-
ate glucose homeostasis. The glucose metabolic rate
measured by the high glucose clamp technique is a
common testing standard[13]. However, a more conve-
nient and economic index is needed for epidemiologi-
cal studies.
It is well known that when hyperinsulinism and high
bold glucose occur together, IR occurs. The insulin sen-
sitive index, which is referred to as the cross product of
FINS and FPG, for example, the HOMA-IR founded
by Mathews[14], 1/FPG*FINS founded by Liguangwei
in 1993 and QUICKI[1/(logFPG*logFINS)] founded
by Katz in 2000[15], largely represents the insulin sensi-
tivity of an organism. Therefore, insulin sensitivity can
be used as an index in epidemiology to observe the as-
sociation of IR and other factors. The results from
our experiment revealed that Houttuynia cordata treat-
ed groups had improved insulin sensitivity, and had
similar effects to Rosiglitazone, an insulin sensitizer
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that has been shown to have curative effects[2].
Changes in Adiponectin Levels
Adiponectin, which is excreted by adipose tissue, plays
an important role in insulin sensitivity and the phlogis-
tic process, and has been linked to adipositas cordis,
type 2 DM and IR[1]. Some studies have shown that pa-
tients with adipositas cordis, type 2 DM and cardiovas-
cular diseases have IR and hyperinsulinism simultane-
ously[16]. In addition, the concentration of adiponectin
in the plasma of these patients was observed to de-
crease[17]. During the development of type 2 DM, the
reduction of adiponectin concentrations in plasma is
equal to the reduction in IR[18]. Adiponectin can be ex-
creted from mature adipose tissue, and adipocytokines,
which have an anti-inflammatory function, increase in-
sulin sensitivity and have a cardioprotective effect. In
addition, adiponectin can inhibit apoptosis of beta
cells induced by inflammatory factors[19]. The reduction
of adiponectin is a key link to type 2 DM[20]. When pa-
tients began to have IR, their serum adiponectin levels
significantly decreased[21-22].
Our results showed that adiponectin levels in the se-
rum and tissue of animals in the model group and all
therapeutic groups were lower than the control group,
which is similar to a previous report[23]. Adiponectin lev-
els in both herbal medicine groups, particularly the
Houttuynia cordata volatile oil group, and both West-
ern medicine groups, were markedly higher than the
model group. These results indicate that Houttuynia
cordata can improve adiponectin levels in rats with
DM.
CTGF Expression
CTGF is highly abundant in the tissues and organs of
humans, especially in the kidney, which has the highest
CTGF concentration. CTGF has many biological func-
tions, including promoting cell multiplication, adjust-
ing extracellular mediators, mediating cell adhesion,
promoting cell phenotype transformation and chemo-
taxis effects. During early stages of DM, kidney hyper-
trophy is a characteristic pathological change[24]. CTGF
plays a very important role in the occurrence and devel-
opment of hypertrophy. An in vitro study has shown
that CTGF not only induces the synthesis of the extra-
cellular matrix (ECM) in interstitial cells, but also me-
diates the creation of enzyme inhibitors stimulated by
transforming growth factor beta, which leads to an in-
crease in the synthesis of the ECM and a decrease in
degradation[25]. Recent clinical research confirmed that
urea and blood CTGF concentrations and the degree
of severity of diabetic nephropathy (urinary albumin
excretion rate) are directly proportional to glomerular
filtration rate[26]. CTGF acts as a fibrosis factor in the
progressive fibrosis of the kidney in diabetic nephropa-
thy by promoting cell mitosis, adjusting the synthesis
of the ECM, and adjusting the restriction point of the
cell cycle [27].
In vitro experiments have also demonstrated cellular ad-
hesion in rats subjected to TGF-β or high glucose con-
ditions, where TGF-β mRNA and albumin levels in-
creased. Furthermore, the addition of recombinant CT-
GF to cell culture medium can induce the synthesis of
the ECM, indicating that high glucose can promote
the process of kidney fibrosis in diabetic nephropathy
by promoting the production of CTGF[28]. In this
study, we showed that Houttuynia cordata volatile oil
can reduce CTGF levels, which may be one of the
mechanisms of relieving kidney injury in diabetic rats.
Currently, there is great interest in the effect of Chi-
nese medicine on diabetic nephropathy. However, few
studies have investigated the effect of Houttuynia cor-
data. Our study has shown that blood glucose, insulin,
adiponectin and CTGF levels in diabetic rats, induced
by the combination of a high-carbohydrate and
high-fat diet, and STZ injection, were affected by
Houttuynia cordata volatile oil, which may function
by reducing IR, adiponectin and CTGF levels. Thus,
Houttuynia cordata volatile oil may have potential ther-
apeutic effects for relieving kidney injury in diabetic
rats.
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